nach oben

Erschienen in:

04.01.2018 | Original Paper

Cost–Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program

verfasst von: Catherine Maulsby, Kriti M. Jain, Brian W. Weir, Blessing Enobun, Melissa Werner, Morey Riordan, David R. Holtgrave, A2C Intervention Team

Erschienen in: AIDS and Behavior | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Linkage to HIV medical care and on-going engagement in HIV medical care are vital for ending the HIV epidemic. However, little is known about the cost–utility of HIV linkage, re-engagement and retention (LRC) in care programs. This paper presents the cost–utility analysis of Access to Care, a national HIV LRC program. Using standard methods from the US Panel on Cost-Effectiveness in Health and Medicine, we calculated the cost–utility ratio. Seven Access to Care programs were cost-effective and two were cost-saving. This study adds to a small but growing body of evidence to support the cost-effectiveness of LRC programs.

Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57(8):1164–71. https://doi.org/10.1093/cid/cit420.CrossRef

White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States. Washington, DC: The White House; 2010. http://www.whitehouse.gov/administration/eop/onap/nhas. Accessed 27 Feb 2016.

White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States: updated to 2020. Washington, DC: The White House; 2015. https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf. Accessed 27 Feb 2016.

Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800. https://doi.org/10.1093/cid/ciq243.CrossRefPubMedPubMedCentral

Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44. https://doi.org/10.1001/jamainternmed.2013.6841.CrossRefPubMed

Higa DH, Crepaz N, Mullins MM, Prevention Research Synthesis Project. Identifying best practices for increasing linkage to, retention, and re-engagement in HIV medical care: findings from a systematic review, 1996–2014. AIDS Behav. 2016;20(5):951–66. https://doi.org/10.1007/s10461-015-1204-x.CrossRef

Liau A, Crepaz N, Lyles CM, Higa DH, Mullins MM, DeLuca J, et al. Interventions to promote linkage to and utilization of HIV medical care among HIV-diagnosed persons: a qualitative systematic review, 1996–2011. AIDS Behav. 2013;17(6):1941–62. https://doi.org/10.1007/s10461-013-0435-y.CrossRefPubMedPubMedCentral

Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(1):99–105. https://doi.org/10.1097/qai.0b013e31825bd862.CrossRefPubMed

Nosyk B, Min JE, Lima VD, Hogg RS, Montaner JS, Group SHAs. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study. Lancet HIV. 2015;2(9):e393–400. https://doi.org/10.1016/s2352-3018(15)00127-7.CrossRefPubMedPubMedCentral

10.

Shah M, Risher K, Berry SA, Dowdy DW. The epidemiologic and economic impact of improving HIV testing, linkage, and retention in care in the United States. Clin Infect Dis. 2016;62(2):220–9. https://doi.org/10.1093/cid/civ801.CrossRefPubMed

11.

Zhang L, Phanuphak N, Henderson K, Nonenoy S, Srikaew S, Shattock AJ, et al. Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study. Lancet HIV. 2015;2(5):e200–7. https://doi.org/10.1016/s2352-3018(15)00020-x.CrossRefPubMed

12.

Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, et al. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS ONE. 2012;7(12):e51993. https://doi.org/10.1371/journal.pone.0051993.CrossRefPubMedPubMedCentral

13.

Kim JJ, Maulsby C, Zulliger R, Jain K, Charles V, et al., Positive Charge Intervention Team. Cost and threshold analysis of positive charge, a multi-site linkage to HIV care program in the United States. AIDS Behav. 2015;19(10):1735–41. https://doi.org/10.1007/s10461-015-1124-9.CrossRef

14.

Jain KM, Zulliger R, Maulsby C, Kim JJ, Charles V, et al., PCI Team. Cost–utility analysis of three U.S. HIV linkage and re-engagement in care programs from positive charge. AIDS Behav. 2016;20(5):973–6. https://doi.org/10.1007/s10461-015-1243-3.CrossRef

15.

Spaulding AC, Pinkerton SD, Superak H, Cunningham MJ, Resch S, Jordan AO, et al. Cost analysis of enhancing linkages to HIV care following jail: a cost-effective intervention. AIDS Behav. 2013;17(Suppl 2):S220–6. https://doi.org/10.1007/s10461-012-0353-4.CrossRefPubMed

16.

Renaud A, Basenya O, de Borman N, Greindl I, Meyer-Rath G. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009;21(11):1388–94. https://doi.org/10.1080/09540120902884042.CrossRefPubMed

17.

Jain KM, Maulsby C, Brantley M, Kim JJ, Zulliger R, et al., Team SIFi. Cost and cost threshold analyses for 12 innovative US HIV linkage and retention in care programs. AIDS Care 2016;28(9):1199–204. https://doi.org/10.1080/09540121.2016.1164294.CrossRef

18.

Health Resources and Services Administration. HIV/AIDS Bureau performance measures. http://hab.hrsa.gov/deliverhivaidscare/coremeasures.pdf. Accessed 10 Oct 2017.

19.

Horberg MA, Aberg JA, Cheever LW, Renner P, O’Brien Kaleba E, Asch SM. Development of national and multiagency HIV care quality measures. Clin Infect Dis. 2010;51(6):732–8. https://doi.org/10.1086/655893 (Epub 19 Aug 2010).CrossRef

20.

Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093–103. https://doi.org/10.1001/jama.2016.12195.CrossRef

21.

Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253–8.CrossRef

22.

Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96. https://doi.org/10.1001/jamainternmed.2014.8180.CrossRefPubMed

23.

Hall HI, Holtgrave DR, Tang T, Rhodes P. HIV transmission in the United States: considerations of viral load, risk behavior, and health disparities. AIDS Behav. 2013;17(5):1632–6. https://doi.org/10.1007/s10461-013-0426-z.CrossRefPubMed

24.

Farnham PG, Holtgrave DR, Gopalappa C, Hutchinson AB, Sansom SL. Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era. J Acquir Immune Defic Syndr. 2013;64(2):e15–8. https://doi.org/10.1097/qai.0b013e3182a5c8d4.CrossRefPubMed

25.

Holtgrave DR, Hall HI, Wehrmeyer L, Maulsby C. Costs, consequences and feasibility of strategies for achieving the goals of the national HIV/AIDS strategy in the United States: a closing window for success? AIDS Behav. 2012;16(6):1365–72. https://doi.org/10.1007/s10461-012-0207-0.CrossRefPubMed

26.

World Health Organization. Choosing interventions that are cost-effective: 2014. http://www.who.int/choice/en/. Accessed 10 Oct 2017.

27.

Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141–5. https://doi.org/10.1093/heapol/czw096.CrossRefPubMed

28.

World Bank. GDP per capita (current US$) 2013. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.

29.

Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637–41. https://doi.org/10.1001/archinte.163.14.1637.CrossRefPubMed

30.

Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med. 1997;127(11):955–65.CrossRef

31.

Walensky RP. Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy. Top HIV Med. 2009;17(4):130–4.PubMed

32.

Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22(5):417–30.CrossRef

Titel: Cost–Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program
verfasst von: Catherine Maulsby
Kriti M. Jain
Brian W. Weir
Blessing Enobun
Melissa Werner
Morey Riordan
David R. Holtgrave
A2C Intervention Team
Publikationsdatum: 04.01.2018
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 11/2018
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-017-2015-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

26.04.2024 | Hüft-TEP | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cost–Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

High Rate of Discontinuation May Diminish PrEP Coverage Among Young Men Who Have Sex with Men

Facilitators and Barriers to Pre-Exposure Prophylaxis (PrEP) Use Among Black Individuals in the United States: Results from the National Survey on HIV in the Black Community (NSHBC)

Missed Opportunities for HIV Prevention: Individuals Who HIV Seroconverted Despite Accessing Healthcare

Explaining HIV Risk Multiplexity: A Social Network Analysis

Beliefs About the End of AIDS, Concerns About PrEP Functionality, and Perceptions of HIV Risk as Drivers of PrEP Use in Urban Sexual Minority Men: The P18 Cohort Study

Community Savings Groups, Financial Security, and HIV Risk Among Female Sex Workers in Iringa, Tanzania

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Update Innere Medizin